^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADP-A2M10

    i
    Company:
    Adaptimmune
    Drug class:
    TCR modulator, MAGE-A10 inhibitor
    Related drugs:
    Apply
    MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC (NCT02592577)
    Phase 1
    Adaptimmune
    Completed
    Last update posted :
    04/09/2021
    Initiation :
    11/01/2015
    Primary completion :
    03/11/2020
    Completion :
    03/17/2021
    EGFR • PD-L1 • ALK • ROS1 • HLA-A
    |
    EGFR mutation • ALK rearrangement • HLA-A*02
    |
    ADP-A2M10
    MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers (NCT02989064)
    Phase 1
    Adaptimmune
    Completed
    Last update posted :
    12/19/2020
    Initiation :
    10/01/2016
    Primary completion :
    12/18/2019
    Completion :
    06/04/2020
    HLA-A
    |
    HLA-A*02
    |
    ADP-A2M10